Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Marvel Biosciences Corp V.MRVL

Alternate Symbol(s):  MBCOF

Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:MRVL)

Marvel Biosciences Secures $300,000 Grant to Advance Groundbreaking Alzheimer's Research

Newsfile 10 hours ago

Marvel Biosciences Announces MB204 Outperforms Approved Drug Trofinetide in a Preclinical Model of Rett Syndrome

Newsfile November 7, 2024

Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism

Newsfile October 10, 2024

Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome

Newsfile August 13, 2024

Marvel Biosciences Announces Stock Option Grants

Newsfile July 25, 2024

Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome

Newsfile July 24, 2024

Marvel Biosciences Closes Private Placement

Newsfile July 19, 2024

Marvel Highlights New Published Research of Its SAB Member Professor David Blum

Newsfile July 9, 2024

Marvel Biosciences Announces Private Placement Update

Newsfile June 21, 2024
View More News ››

Opinion & Analysis (TSXV:MRVL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:MRVL)

Marvel Biosciences Initiates Formulation Development

Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary...
Betteryear2 - April 6, 2022

Fox In The Hen House?

Check out the EHT forum and learn something.
suomynona - August 4, 2021
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »